Therefore, vivax malaria patients with the defective CYP2D6 function would be at increased risk for therapeutic failure (relapses) regardless of proper treatment regimens with primaquine [14, 19, 20]. Here, CYP2D6 is linked to Plasmodium vivax malaria.